Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
But we were informed by Charty that posting opinions has no effect on share prices.
Now Nige you seem awfully anxious these days no need to throw your toys out of the pram for heavens sake man get a grip!
RNS just released on director holdings Dr Christopher Batterham dumped 18,745 shares at 22.94p in addition to his 24p buy back entitlements not good imho!...😔
RNS just released on director holdings Dr Christopher Batterham dumped 18,745 shares at 22.94p in addition to his 24p buy back entitlements not good imho!...😔
EC
This BB is for discussing the business prospects and not for spamming the BB day in day out.
You don't add any new material it's just long winded copy and paste and given the sheer lack of replies no one is interested.
Equally posting 'share price up 4%' it's just really bizarre behaviour!
EC
Only volume sales occur when Parsortix is fully validated by the FDA until that point research use only has very limited revenue generation potential and hence low cash yield. Thats why Angle are heading for a cash placement.
However you want to slice and dice things it amounts to the same thing without validation there's no commercial traction through Parsortix machine sales.
XenOn
I actually said Nige in my earlier post as below.
"Nige you need to stop with these childish outbursts throwing your toys out of the pram!"
And you responded referring Nigwit lol'
Xenon: "You're talking BS"
TG2D "look, it's Nigwit"
____________________
Another sock puppet account unveiled lol!
Nige you need to stop with these childish outbursts throwing your toys out of the pram!
Charty
Tender buyback of £30m doesn't conclude till 25th April when funds returned to investors likewise on going £3m on market buyback to prop the share price to 21p will continue through till no doubt pate May early June possibly longer until that cash fund is fully utilised we can't speculate where the share price will land without news on any new commercial deals that will plug the £7m to £10m revenue shortfall needed to reach cash breakeven next year!
Who is driving demand the £3m on market buy back, duh!
Looks like they are trying to set a floor share price of around 21p hence expect share price following 25th April when funds are returned to bounce around 24p for a few weeks then the price falls to 21p but the £3m market support will only extend this by around 10 days...should interesting tonsee where the share price lands end May early June when the dust has settled so to speak!
WiggyP
Member Since
25th Jan 2024
Around 30 odd posts on SYME with a couple on RTOP all negative that figures.
Now ignored!
WiggyP
I referenced clearly to Banoco BPM imo taking an equity stake why are you referring to other institutional imvestors that wasn't my point so why mention it, its irrelevant for now, unlike Banoco BPM where there is an establiahed relationship?
A lack of posts 📫 today seems everyone is either out enjoying the Spring Day or most SYME investors are flagging which is not surprising given the disappointments and roller coaster ride over the last few years which is understandable.
However I believe things are about to change for the better given the long painful period of delays, failed delivery, and general dissatisfaction with lack of progress made.
One needs to understand not to underestimate the complexity abd challenges this WL IM project had to overcome from regulatory, legal, accounting, tax, audit, funding, crypto currency based electronic trading, the number of different jurisdictions involved, the time and challenges needed with third party banks ajd their clients needs, and time required to finalise product delivery and contract completion and that's all on top of designing and delivering a software product from scratch to record, track, and monitor IM transactions from start to finish.
Hence don't be surprised if things move forward now quicker than expected in the form of Banoco BPM taking an equity stake in SYME and offering a working capital credit line...
It certainly won't initially ramp up fast but once the ship is stabalised and direction set things will slowly gather momentum and six months from now we may well be in a completely different situation.
In addition having Banoco BPM onboard as a major institutional investor would provide greater corporate oversight and accountability addressing investors concerns over corporate governance.
Assuming that Banoco BPM take a 20%+ equity stake in the next few weeks this would also support a working capital credit line with the funding covering both the imminent ongoing operating cash requirements and diversifying funding away from dilutive equity loans with third parties. Having the bank onboard as a key instutional investor would also provide more financial stability as WL IM is slowly adopted by the bank but also rolled out to other banks.
This proposal may seem odd at first but as Banoco BPM can't probibit SYME approaching the banks competitors it makes sense for them to take a stake in the future equity returns from a fast growing fintech business which is exactly what the bank has done with other key fintech suppliers.
EC
It's a fundamental question without FDA approval you don't have business there is only a limited number of opportunities to sell the Parsortix machine to labs to use it for 'research' purposes only.
Widescale lab adoption will only take place when labs receive a product that is ideally fully FDA approved to 'test' most if not all major cancer groups without which AGL will never generate sufficent revenues to breakeven let alone generate profits.
Thompi
There is a distinction between 'research' use and 'testing' to identify a cancer and suitable drug treatments..
Too many here are unable to differiante between the two that's a fundamental misunderstanding
If you have any clear facts with links showing that Parsortix is fully FDA approved for testing most if not all cancer groups then I suggest you share the link to the source that clearly states such..
As far as I am aware Parsortix is only FDA approved for testing for breast cancer which accounts for 4% of all cancers..
It wouldn't surprise me if its announced Banoco BPM are taking a 20% equity stake in SYME.
Sandy
Oh dear Parsortix approved only for testing 4% of cancers, FACT!
Any ideas why your myopic view aligns to the lack of Parsortix machine sales now?
When you guys actually understand the industry, what clinical approved lab validation involves in the USA rather than simply copy and pasting the same testing results which reflects 'research' only not FDA approval for Parsortix to be used to test for the remaining 96% of other cancers it is currently NOT FDA approved for!
You simply can't shirk FDA approval seriously!